Angle Share Discussion Threads

[sawney] 31/1/2024 12:04

Yes...he was a real go getter...but as you say...I think he was defeated by the backhanders....

[bones698] 31/1/2024 11:56

Sawney aye had some good times on that BB back in the day . Actually in Scotland seeing a friend from that BB . They were unlucky tbh the decision on Iraq which looked nailed on got squashed probably due to big brown envelopes from the big oil companies there .
Remo didn't have his glory with Azerbaijan though and I met him several times . One of the better CEOs I've come across .

[sawney] 31/1/2024 08:14

Bones

Remember them well...another deeply frustrating experience...:-)

Sadly, Steve Remp died 3 years ago....

[bones698] 31/1/2024 07:00

Are you the same htrocka from ramco days ? This is the proper bones not the impersonator btw

[htrocka2] 30/1/2024 22:08

'Oh dear!

Another day watching paint dry!'

Never mind, the serious investor can alway have a good laugh at your posts...It's better than watching paint dry.

[bones699] 30/1/2024 17:31

Oh dear!

Another day watching paint dry!

[pj84] 30/1/2024 16:46

raddersSandy thanks for the Trinity Delta research note link, it is paid for research so always needs to be taken with a pinch of salt, nevertheless a very useful read and summary.

[5oletrader] 30/1/2024 16:22

Tomorrow - 12:30 pmJourney of a DDR Patient SampleDe-risking Preclinical and Clinical Research.• Brett SwansigerChief Commercial Officer, ANGLE Europe Limited(Glad to see him steeping up here)• https://angleplc.com/team/brett-swansiger/-SYNOPSIS:• Advanced CTC isolation with Parsortix FDA-510k cleared capture technology• Integration of CTCs with known DDR biomarker assays• Provide strategies to minimize risks in the development of targeted DDR therapies• Explore future approaches to evaluate DDR inhibitors based upon responses guided by Parsortix enriched CTCs• https://ddr-inhibitors-summit.com/program/day-one/

[john henry] 30/1/2024 15:34

Got to be a Tim to be that dim.

MMs will skin them everyday.

[bones698] 30/1/2024 14:48

Nice up here too ATM just chilling having a coffee taking in the sights .

[boris cobaka] 30/1/2024 14:19

Hear hear!

[bagpuss67] 30/1/2024 14:18

Lol... And buy a duster as well

[htrocka2] 30/1/2024 14:16

Buy'em... stick them in draw and wait for the updates.

[5oletrader] 30/1/2024 13:04

If anyone is interested? (For Context)-PROSTATE CANCER:• The Urology Group has a news story here - at 1m32s to 1m37s "I DO HAVE ABIT OF FAITH NOW THAT THERE IS THE NEXT THING COMING ALONG" - make of that what you will? How about AGLs CTC based liquid biopsy which potentially offers a unique opportunity to triage men with elevated PSA?• https://youtu.be/It2DX91ufmM?si=BPMTmPkvqIEvCuv2-• Reenforcing the significance of AGLs partnership with MidLantic Urology - (part of the above Urology Group)• https://www.urologygroup.com/corporate-overview/• The Urology Group is an affiliate of Solaris Health.• https://solarishealthpartners.com/about-us/-RE CURRENT SCREENING:• In the United States, the Preventive Services Task Force recommends that all men between the ages of 55-69 years be offered annual prostate screening using a blood-based prostate specific antigen (PSA) test.• https://angleplc.com/translational-research/prostate-cancer/-SCREENING PROCESS FLAWED?:• While prostate cancer mortality rates have declined since the advent of PSA testing, it is UNCERTAIN what proportion of this is due to PSA screening.• The best available evidence from randomized trials found that screening has at most a small benefit in reducing prostate cancer mortality. SCREENING has NO BENEFIT in REDUCING overall MORTALITY.• https://www.uptodate.com/contents/screening-for-prostate-cancer#H2191332858-SIGNIFICANT OPPORTUNITY:• Dr Jose Moreno, Principal Investigator, MidLantic Urology, commented:• "Even though PSA is a valuable marker of response to prostate cancer treatment, its role in screening is modest at best and can lead to both overdiagnosis of clinically indolent prostate cancer and underdiagnosis of clinically significant prostate cancer which can result in increased rates of local failure and metastatic disease.• ANGLE's Parsortix platform has the potential to enable molecular characterisation of the cancer using a blood test in patients undergoing both traditional ultrasound biopsies and MRI fusion biopsies. The preliminary data suggest that we may be able to create an assay for the detection of clinically significant prostate cancer that has high specificity and sensitivity. Moreover, the assay can be customized to operate in a wide spectrum of prostate cancer disease states, including pre-prostate biopsy, after a negative biopsy, active surveillance, after local failure, and in early and late metastatic disease states. If our results are validated, our MidLantic Urology patients and Solaris Health affiliates may be the first to benefit from these developments."-NEW DRUG ON THE BLOCK:• Novartis - Pluvicto• https://www.us.pluvicto.com/about-pluvicto/how-pluvicto-works/• Patient Monitoring? Another commercial opportunity for AGL to chase?-ATB

[john henry] 30/1/2024 10:50

Enjoy a great day Dave, Edinburgh is a Wonderful City

[john henry] 30/1/2024 10:07

Added into DEST on upcoming XF73 Dermal news.
Apparently DEST have the data waiting on NIAID to release
As you can read initial trial results where outstanding, NIAID decided to extend the trial into wounds and burns.

DYOR Note This Share is extremely tightly held NMS 1500 shares

And there has been a large seller around for months

[john henry] 30/1/2024 09:41

well Dave i just took a trade on HE1 in 1.12p out 1.6p 5 MIN

Thats me done for the day.

[john henry] 30/1/2024 09:37

Will 15.75p hold as support ? .

[john henry] 30/1/2024 09:25

Dave your intraday pattern rings true, however imho there are still sellers from pre spike and spike.
Its not just this stock Dave its virtually the same pattern on every small cap.
A slight rise and sellers pile out. Thankfully they can only sell once.
Todays broker note brought out a few buyers however as soon as they were exhausted the sellers piled in.

Markets are indeed a very strange beast, AGLs recent excellent RNSs may just as well never happened.